ARQT vs BMY
ARQT: Arcutis Biotherapeutics is a commercial-stage dermatology company delivering innovative, targeted treatments for immune-mediated skin conditions. BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally.
Side-by-side fundamentals
| Metric | ARQT | BMY | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $25.08 | $67.01 | |
| Market cap as of 2026-08-24 | $3.2B | $136.9B | |
| P/E as of 2026-08-24 | 113.86 | 14.21 | BMY lower |
| PEG as of 2026-08-24 | n/a | -8.67 | |
| Net margin as of 2026-08-24 | +6.2% | +18.9% | BMY higher |
| Gross margin as of 2026-08-24 | +91.1% | +71.7% | ARQT higher |
| Operating margin as of 2026-08-24 | +7.4% | +25.5% | BMY higher |
| ROE as of 2026-08-24 | +15.0% | +46.8% | BMY higher |
| ROA as of 2026-08-24 | +6.5% | +10.3% | BMY higher |
| Debt / equity as of 2026-08-24 | 0.49 | 1.93 | ARQT lower |
| Revenue growth (YoY) as of 2026-08-24 | +76.1% | +3.1% | ARQT higher |
| Revenue CAGR (3y) SEC XBRL | +367.3% | +1.4% | ARQT higher |
| Dividend yield as of 2026-08-24 | n/a | +4.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-24 | 1.59 | 0.18 | |
| 1-year return as of 2026-08-21 close | +58.8% | +38.4% | ARQT higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.